Abstract
In this manuscript, three-dimensional quantitative structure-activity relationship (3D-QSAR) studies using comparative molecule field analysis (CoMFA) techniques were applied to provide the structural information of Bcl-2 inhibitors. The CoMFA model obtained from the training set were all statistically significant with the cross-validated coefficients (q2) of 0.568 and conventional coefficients (r2) of 0.991. The contribution of steric field and the electrostatic field is 0.635 and 0.365, respectively. The 3D-QSAR model was furthermore validated by a test set of 6 molecules. The predicted correlation coefficient (r2 pred) on the test set is 0.582. Therefore, the 3D-QSAR models built may be used to exhibit the necessary ligand-based structural environment as well as to design novel Bcl-2 inhibitors with increasing activities.
Keywords: CoMFA, Bcl-2 protein, inhibitors, 3D-QSAR, Comparative Molecular Field Analysis, GPCRs, Sketch Molecule, Gasteiger-Huckel, Partial Least Square, r2pred, HMLP, electrostatic field, leave-one-out, Tripos force fieldCoMFA, Bcl-2 protein, inhibitors, 3D-QSAR, Comparative Molecular Field Analysis, GPCRs, Sketch Molecule, Gasteiger-Huckel, Partial Least Square, r2pred, HMLP, electrostatic field, leave-one-out, Tripos force field
Protein & Peptide Letters
Title: 3D-QSAR Study on a Series of Bcl-2 Protein Inhibitors Using Comparative Molecular Field Analysis
Volume: 18 Issue: 5
Author(s): Xuben Hou, Jintong Du, Hao Fang and Minyong Li
Affiliation:
Keywords: CoMFA, Bcl-2 protein, inhibitors, 3D-QSAR, Comparative Molecular Field Analysis, GPCRs, Sketch Molecule, Gasteiger-Huckel, Partial Least Square, r2pred, HMLP, electrostatic field, leave-one-out, Tripos force fieldCoMFA, Bcl-2 protein, inhibitors, 3D-QSAR, Comparative Molecular Field Analysis, GPCRs, Sketch Molecule, Gasteiger-Huckel, Partial Least Square, r2pred, HMLP, electrostatic field, leave-one-out, Tripos force field
Abstract: In this manuscript, three-dimensional quantitative structure-activity relationship (3D-QSAR) studies using comparative molecule field analysis (CoMFA) techniques were applied to provide the structural information of Bcl-2 inhibitors. The CoMFA model obtained from the training set were all statistically significant with the cross-validated coefficients (q2) of 0.568 and conventional coefficients (r2) of 0.991. The contribution of steric field and the electrostatic field is 0.635 and 0.365, respectively. The 3D-QSAR model was furthermore validated by a test set of 6 molecules. The predicted correlation coefficient (r2 pred) on the test set is 0.582. Therefore, the 3D-QSAR models built may be used to exhibit the necessary ligand-based structural environment as well as to design novel Bcl-2 inhibitors with increasing activities.
Export Options
About this article
Cite this article as:
Hou Xuben, Du Jintong, Fang Hao and Li Minyong, 3D-QSAR Study on a Series of Bcl-2 Protein Inhibitors Using Comparative Molecular Field Analysis, Protein & Peptide Letters 2011; 18 (5) . https://dx.doi.org/10.2174/092986611794927992
DOI https://dx.doi.org/10.2174/092986611794927992 |
Print ISSN 0929-8665 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5305 |

- Author Guidelines
- Bentham Author Support Services (BASS)
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Determinants of Anti-Cancer Effect of Mitochondrial Electron Transport Chain Inhibitors: Bioenergetic Profile and Metabolic Flexibility of Cancer Cells
Current Pharmaceutical Design Estrogen and Female Lower Urinary Tract Dysfunction
Current Women`s Health Reviews Iron Metabolism: A Promising Target for Antibacterial Strategies
Recent Patents on Anti-Infective Drug Discovery TAP-Independent MHC Class I Presentation
Current Immunology Reviews (Discontinued) Editorial [Hot topic: Novel Proteins and Pathways as Anti-Cancer Therapeutic Targets (Guest Editor: Q. Ping Dou)]
Current Protein & Peptide Science Peroxisome Proliferator-Activated Receptor-γ and Its Ligands in the Treatment of Tumors in the Nervous System
Current Stem Cell Research & Therapy Fine-tuning of microRNAs in Type 2 Diabetes Mellitus
Current Medicinal Chemistry Targeting Nanomedicine to Brain Tumors: Latest Progress and Achievements
Current Pharmaceutical Design Identification of High-affinity Small Molecules Targeting Gamma Secretase for the Treatment of Alzheimer’s Disease
Current Topics in Medicinal Chemistry The Tangled Mitochondrial Metabolism in Cancer: An Innovative Pharmacological Approach
Current Medicinal Chemistry Recent Advances in Chemical Genomics
Current Medicinal Chemistry Recent Patents of Gene Mutation Relative to JAK/STAT Pathway and Their Implication in Myeloproliferative Diseases
Recent Patents on DNA & Gene Sequences The Urokinase Receptor Interactome
Current Pharmaceutical Design Targeted Therapies for Autosomal Dominant Polycystic Kidney Disease
Current Medicinal Chemistry Impact of Probiotics and Prebiotics on Colon Cancer: Mechanistic Insights and Future Approaches
Current Cancer Therapy Reviews Gene Therapy for Primary Immunodeficiency Diseases: Recent Progress and Misgivings
Current Pharmaceutical Design DNA Methylation: An Epigenetic Insight into Type 2 Diabetes Mellitus
Current Pharmaceutical Design Cytotoxic Effects of the Monomer and Dimer of 3, 4-seco-ent-kaurene from Croton Micans and their Interaction with Antitumoral Drugs on Cellular Line of Human Prostate Cancer
Letters in Drug Design & Discovery Ethical and Social Issues in Pharmacogenomics Testing
Current Pharmaceutical Design Proteomics Approach to Illustrate Drug Action Mechanisms
Current Drug Discovery Technologies